OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press103610.17650/1818-8346-2025-20-2-126-137SUPPORTIVE THERAPY ASPECTSАСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИInvasive aspergillosis in patients with acute myeloid leukemia: difficulties in choosing first-line therapy in real clinical practice and pharmacoeconomic analysis of the feasibility of using new antifungal drugsИнвазивный аспергиллез у пациентов с острым миелоидным лейкозом: сложности выбора первой линии терапии в реальной клинической практике и фармакоэкономический анализ целесообразности применения новых антимикотиковhttps://orcid.org/0000-0002-9709-380XOsipovYu. S.ОсиповЮ. С.
Russian Federation

Yuriy Sergeevich Osipov

2 Akkuratova St., Saint Petersburg 197341 

Юрий Сергеевич Осипов 

197341 Санкт-Петербург, ул. Аккуратова, 2 

yosipov88@yandex.ruhttps://orcid.org/0000-0003-2084-4545AntonovA. A.АнтоновА. А.
Russian Federation

Artem Alekseevich Antonov

Build. 2, 11 Timura Frunze St., Moscow 119034

Артем Алексеевич Антонов 

119034 Москва, ул. Тимура Фрунзе, 11, корп. 2 

antonov@r-healthconsult.comhttps://orcid.org/0000-0003-1536-9313IvanovV. V.ИвановВ. В.
Russian Federation

2 Akkuratova St., Saint Petersburg 197341

197341 Санкт-Петербург, ул. Аккуратова, 2 

SalogubG. N.СалогубГ. Н.
Russian Federation

2 Akkuratova St., Saint Petersburg 197341

197341 Санкт-Петербург, ул. Аккуратова, 2 

V.A. Almazov National Medical Research Centre, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава РоссииR-Health Consult220520252021261372005202520052025https://oncohematology.abvpress.ru/ongm/article/view/1036

The article discusses the epidemiology and difficulties of diagnosing invasive aspergillosis in patients with acute myeloid leukemia, the role of pharmacokinetic and pharmacogenetic studies in choosing the optimal treatment regimen, and an attempt at pharmacoeconomic analysis to create an optimal treatment strategy for this complication.

В статье рассмотрены эпидемиология и сложности диагностики инвазивного аспергиллеза у пациентов с острым миелоидным лейкозом, роль фармакокинетических и фармакогенетических исследований в выборе оптимального режима терапии. Предпринята попытка фармакоэкономического анализа для создания оптимальной стратегии лечения данного осложнения.

invasive aspergillosisinvasive mycosispharmacoeconomic analysisинвазивный аспергиллезизавуконазолфармакоэкономический анализNganthavee V., Phutthasakda W., Atipas K. et al. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes [published correction appears in Support Care Cancer 2019;27(9):3623]. Support Care Cancer 2019;27(9):3613–22. DOI: 10.1007/s00520-019-04720-5Klyasova G.A., Okhmat V.A., Vasilyeva V.A. et al. Invasive mycoses in patients with acute leukemia and in recipients of hematopoietic stem cells. Results of a multicenter prospective observational study in Russia (RIFI). Gematologiya i transfuziologiya = Hematology and Transfusiology 2016;61(1–S1):19. (In Russ.).Клясова Г.А., Охмат В.А., Васильева В.А. и др. Инвазивные микозы у больных острыми лейкозами и у реципиентов гемопоэтических стволовых клеток. Результаты многоцентрового проспективного наблюдательного исследования в России (RIFI). Гематология и трансфузиология 2016;61(1–S1):19.Zhang A., Johnson T., Abbott D. et al. Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine. Open Forum Infect Dis 2022;9(10):ofac486. DOI: 10.1093/ofid/ofac486Wang S.T., Chou C.H., Chen T.T. et al. High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia. Front Cell Infect Microbiol 2022;12:1012334. DOI: 10.3389/fcimb.2022.1012334Maertens J.A., Raad II, Marr K.A. et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016;387(10020):760–9. DOI: 10.1016/S0140-6736(15)01159-9Tissot F., Agrawal S., Pagano L. et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017;102(3):433–44. DOI: 10.3324/haematol.2016.152900Ullmann A.J., Aguado J.M., Arikan-Akdagli S. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24(Suppl 1):e1–38. DOI: 10.1016/j.cmi.2018.01.002Fadhel M., Patel S.V., Liu E. et al. Disseminated pulmonary with isolated muscular mucormycosis in an acute myeloid leukemia patient: a case report and literature review. Am J Case Rep 2019;20:1210–5. DOI: 10.12659/AJCR.916864Klimko N.N., Khostelidi S.N., Shadrivova O.V. et al. Mucormycosis in oncohematology patients (results of the prospective study). Onkogematologiya = Oncohematology 2017;12(2):14–22. (In Russ.). DOI: 10.17650/1818-8346-2017-12-2-14-22Климко Н.Н., Хостелиди С.Н., Шадривова О.В. и др. Инвазивный мукормикоз у онкогематологических больных (результаты проспективного исследования). Онкогематология 2017;12(2):14–22. DOI: 10.17650/1818-8346-2017-12-2-14-22Marty F.M., Ostrosky-Zeichner L., Cornely O.A. et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016;16(7):828–37. DOI: 10.1016/S1473-3099(16)00071-2Malhotra S., Kumari R., Chauhan A.K. et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid sample from suspected patients of invasive pulmonary aspergillosis. Indian J Pathol Microbiol 2021;64(4):732–4. DOI: 10.4103/IJPM.IJPM_985_20Guegan H., Robert-Gangneux F., Camus C. et al. Improving the diagnosis of invasive aspergillosis by the detection of Aspergillus in broncho-alveolar lavage fluid: comparison of non-culture-based assays. J Infect 2018;76(2):196–205. DOI: 10.1016/j.jinf.2017.11.011Shadrivova O.V., Khostelidi S.N., Shagdileva E.V. et al. Mucormycosis and invasive aspergillosis in patients with oncohematological pathology in Russia (results of a multicenter study). Problemy meditsinskoy mikologii = Problems in Medical Mycology 2024;26(2):26–37. (In Russ.). DOI: 10.24412/1999-6780-2024-2-26-37Шадривова О.В., Хостелиди С.Н., Шагдилева Е.В. и др. Мукормикоз и инвазивный аспергиллез у пациентов с онкогематологической патологией в России (результаты многоцентрового исследования). Проблемы медицинской микологии 2024;26(2):26–37. DOI: 10.24412/1999-6780-2024-2-26-37Markelov V.V., Rogacheva Yu.A., Popova M.O. et al. Invasive aspergillosis caused by Aspergillus non-fumigatus after allogeneic hematopoietic stem cell transplantation. Zhurnal infectologii = Journal Infectology 2022;14(5):5–13. (In Russ.). DOI: 10.22625/2072-6732-2022-14-5-5-13Маркелов В.В., Рогачева Ю.А., Попова М.О. и др. Инвазивный аспергиллез, обусловленный Aspergillus non-fumigatus, у взрослых пациентов после аллогенной трансплантации гемопоэтических стволовых клеток. Журнал инфектологии 2022;14(5):5–13. DOI: 10.22625/2072-6732-2022-14-5-5-13Wang Y., Zhang L., Zhou L. et al. Epidemiology, drug susceptibility, and clinical risk factors in patients with invasive aspergillosis. Front Public Health 2022;10:835092. DOI: 10.3389/fpubh.2022.835092Son H.J., Song J.S., Choi S. et al. A comparison of histomorphologic diagnosis with culture and immunohistochemistry-based diagnosis of invasive aspergillosis and mucormycosis. Infect Dis (London) 2020;52(4):279–83. DOI: 10.1080/23744235.2020.1716063Sangoi A.R., Rogers W.M., Longacre T.A. et al. Challenges and pitfalls of morphologic identification of fungal infections in histologic and cytologic specimens: a ten-year retrospective review at a single institution. Am J Clin Pathol 2009;131(3):364–75. DOI: 10.1309/AJCP99OOOZSNISCZGuarner J., Brandt M.E. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 2011;24(2):247–80. DOI: 10.1128/CMR.00053-10Klimko N., Khostelidi S., Shadrivova O. et al. Contrasts between mucormycosis and aspergillosis in oncohematological patients. Med Mycol 2019;57(Supplement_2):S138–44. DOI: 10.1093/mmy/myy116Alexander B.D., Lamoth F., Heussel C.P. et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/ MSGERC. Clin Infect Dis 2021;72(Suppl 2):S79–88. DOI: 10.1093/cid/ciaa1855Lewis R.E., Stanzani M., Morana G., Sassi C. Radiology-based diagnosis of fungal pulmonary infections in high-risk hematology patients: are we making progress? Curr Opin Infect Dis 2023;36(4):250–6. DOI: 10.1097/QCO.0000000000000937Murray J., Lu Z.A., Miller K. et al. Dual disseminated aspergillosis and mucormycosis diagnosed at autopsy: a report of two cases of coinfection and a review of the literature. J Fungi (Basel) 2023;9(3):357. DOI: 10.3390/jof9030357Shadrivova O.V., Khostelidi S.N., Borzova Yu.V. et al. Combination of invasive aspergillosis and mucormycosis in oncohematological patients. Onkogematologiya = Oncohematology 2017;12(4):8–17. (In Russ.). DOI: 10.17650/1818-8346-2017-12-4-8-17Шадривова О.В., Хостелиди С.Н., Борзова Ю.В. и др. Сочетание инвазивного аспергиллеза и мукормикоза у онкогематологических больных. Онкогематология 2017;12(4):8–17. DOI: 10.17650/1818-8346-2017-12-4-8-17Chamilos G., Lewis R.E., Kontoyiannis D.P. et al. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47(4):503–9. DOI: 10.1086/590004Fakhim H., Badali H., Dannaoui E. et al. Trends in the prevalence of amphotericin B-resistance (AmBR) among clinical isolates of Aspergillus species. J Mycol Med 2022;32(4):101310. DOI: 10.1016/j.mycmed.2022.101310De Francesco M.A. Drug-resistant Aspergillus spp.: a literature review of its resistance mechanisms and its prevalence in Europe. Pathogens 2023;12(11):1305. DOI: 10.3390/pathogens12111305Klyasova G.A. Novel treatment possibilities of invasive aspergillosis. Onkogematologiya = Oncohematology 2021;16(4):31–9. (In Russ.). DOI: 10.17650/1818-8346-2021-16-4-31-39Клясова Г.А. Новые возможности терапии инвазивного аспергиллеза. Онкогематология 2021;16(4):31–9. DOI: 10.17650/1818-8346-2021-16-4-31-39Imbert S., Portejoie L., Pfister E. et al. A multiplex PCR and DNA-sequencing workflow on serum for the diagnosis and species identification for invasive aspergillosis and mucormycosis. J Clin Microbiol 2023;61(1):e0140922. DOI: 10.1128/jcm.01409-22Li X., Hu Q., Xu T. Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis. Front Pharmacol 2024;15:1368274. DOI: 10.3389/fphar.2024.1368274Danion F., Jullien V., Rouzaud C. et al. Is it time for systematic voriconazole pharmacogenomic investigation for central nervous system aspergillosis? Antimicrob Agents Chemother 2018;62(9):e00705–18. DOI: 10.1128/AAC.00705-18Mirzaev K.B., Zelenskaya E.M., Barbarash O.L. et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med 2017;10:107–14. DOI: 10.2147/PGPM.S126305Moriyama B., Obeng A.O., Barbarino J. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther 2017;102(1):45–51. DOI: 10.1002/cpt.953Blanco-Dorado S., Maroñas O., Latorre-Pellicer A. Impact of CYP2C19 genotype and drug interactions on voriconazole plasma concentrations: a Spain pharmacogenetic-pharmacokinetic prospective multicenter study. Pharmacotherapy 2020;40(1):17–25. DOI: 10.1002/phar.2351Kaindl T., Andes D., Engelhardt M. et al. Variability and exposure- response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother 2019;74(3):761–7. DOI: 10.1093/jac/dky463Kaindl T., Andes D., Engelhardt M. et al. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother 2019;74(3):761–7. DOI: 10.1093/jac/dky463Vergidis P., Sendi P., Alkhateeb H.B., Nguyen M.H. How do I manage refractory invasive pulmonary aspergillosis. Clin Microbiol Infect 2024;30(6):755–61. DOI: 10.1016/j.cmi.2024.01.015Donnelly J.P., Chen S.C., Kauffman C.A. et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020;71(6):1367–76. DOI: 10.1093/cid/ciz1008Floros L., Pagliuca A., Taie A.A. et al. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom. J Med Econ 2020;23(1):86–97. DOI: 10.1080/13696998.2019.1638789Floros L., Kuessner D., Posthumus J. et al. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. BMC Infect Dis 2019;19(1):134. DOI: 10.1186/s12879-019-3683-2Maertens J.A., Girmenia C., Brüggemann R.J. et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 2018;73(12):3221–30. DOI: 10.1093/jac/dky286Vallejo C., Jarque I., Fortun J. et al. IFISTRATEGY: Spanish national survey of invasive fungal infection in hemato-oncologic patients. J Fungi 2023;9(6):628. DOI: 10.3390/jof9060628Naser A., Bilbisi M., Mousa R. EE487 cost-effectiveness analysis of isavuconazole versus liposomal amphotericin for the treatment of invasive mucormycosis in Jordan. Value in Health 2023;26(12):S145.Alqarihi A., Kontoyiannis D.P., Ibrahim A.S. Mucormycosis in 2023: an update on pathogenesis and management. Front Cell Infect Microbiol 2023;13:1254919. DOI: 10.3389/fcimb.2023.1254919Petrikkos G.L. Lipid formulations of amphotericin B as first line treatment of zygomycosis. Clin Microbiol Infect 2009;15 Suppl 5: 87–92. DOI: 10.1111/j.1469-0691.2009.02987.xPopova M.O., Rogacheva Yu.A. Mucormycosis: modern diagnostics and treatment, existing problems and new trends in antifungal therapy. Klinicheskaya mikrobiologiya i antimicrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy. 2021;23(3):226–38. (In Russ.). DOI: 10.36488/cmac.2021.3.226-238Попова М.О., Рогачева Ю.А. Мукормикоз: современные возможности диагностики и лечения, существующие проблемы и новые тенденции в терапии. Клиническая микробиология и антимикробная химиотерапия 2021;23(3):226–38. DOI: 10.36488/cmac.2021.3.226-238